コンテンツへスキップ
Merck

I0505

Sigma-Aldrich

Anti-IκBα antibody produced in rabbit

IgG fraction of antiserum, buffered aqueous solution

別名:

Anti-AUTSX3, Anti-MRX16, Anti-MRX79, Anti-MRXS13, Anti-MRXSL, Anti-PPMX, Anti-RS, Anti-RTS, Anti-RTT

ログイン組織・契約価格を表示する


About This Item

MDL番号:
UNSPSCコード:
12352203
NACRES:
NA.41

由来生物

rabbit

品質水準

結合体

unconjugated

抗体製品の状態

IgG fraction of antiserum

抗体製品タイプ

primary antibodies

クローン

polyclonal

形状

buffered aqueous solution

分子量

antigen 36 kDa

化学種の反応性

mouse, human, rat

テクニック

microarray: suitable
western blot: 1:2,000 using a whole extract of human epidermal carcinoma A431 cells
western blot: 1:2,000 using a whole extract of human epitheloid carcinoma HeLa cells

UniProtアクセッション番号

輸送温度

dry ice

保管温度

−20°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

human ... NFKBIA(4792)
mouse ... Nfkbia(18035)
rat ... Nfkbia(25493)

詳細

The gene NFKBIA (nuclear factor of κ light polypeptide gene enhancer B-cells inhibitor-α) encodes the α member of the NF-κ-B inhibitor family IκB, which also consists of IκBβ and IκBε. NFKBIA is also referred to as IκBα. It is the strongest inhibitor of nuclear NF-κB activity among these members. Specific phosphorylation of the inhibitor IκBα at Ser32 and Ser36, its ubiubiquitination and subsequent proteolytic degradation is necessary for the activation of NF-κ-B. It is localized to the cytosol, where it retains NF-κB. Polymorphism in this gene is linked to recurrent acute rejections in liver transplant recipients. Mutations in this gene have been linked to autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. The gene NFKBIA is mapped to human chromosome 14q13.

免疫原

ヒトIκBαのC末端アミノ酸297~317に相当する合成ペプチド(N末端リジン付加)のKLH結合体。

アプリケーション

Anti-IκBα antibody produced in rabbit has been used in western blotting.

生物化学的/生理学的作用

Specific phosphorylation of the inhibitor IκBα at Ser32 and Ser36, its ubiquitination and subsequent proteolytic degradation is necessary for the activation of NF-κ-B. Polymorphism in this gene is linked to recurrent acute rejections in liver transplant recipients. Mutations in this gene have been linked to autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency.

物理的形状

0.01 M PBS溶液(pH 7.4, 15 mMアジ化ナトリウム含有)。

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください

保管分類コード

10 - Combustible liquids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

The effects of acute oral glutamine supplementation on exercise-induced gastrointestinal permeability and heat shock protein expression in peripheral blood mononuclear cells
Zuhl M, et al.
Cell Stress & Chaperones, 20(1), 85-93 (2015)
Marianna Romzova et al.
Human immunology, 67(9), 706-713 (2006-09-28)
Nuclear factor kappa B (NFkappaB) is an important transcription factor that together with its inhibitor (IkappaB) participates in the activation of genes involved in immune responses. We examined the CA repeat polymorphism of the NFKB1 gene (encoding for NFkappaB) and
Micah N Zuhl et al.
Journal of applied physiology (Bethesda, Md. : 1985), 116(2), 183-191 (2013-11-29)
The objectives of this study are threefold: 1) to assess whether 7 days of oral glutamine (GLN) supplementation reduces exercise-induced intestinal permeability; 2) whether supplementation prevents the proinflammatory response; and 3) whether these changes are associated with upregulation of the
A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene
Klein W, et al.
International Journal of Colorectal Disease, 19(2), 153-156 (2004)
Pavel I Makarevich et al.
PloS one, 13(5), e0197566-e0197566 (2018-05-23)
Since development of plasmid gene therapy for therapeutic angiogenesis by J. Isner this approach was an attractive option for ischemic diseases affecting large cohorts of patients. However, first placebo-controlled clinical trials showed its limited efficacy questioning further advance to practice.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)